Drug Profile


Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Preclinical Pain
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 24 Jan 2017 UCB Pharma completes a phase III trial in Partial epilepsies in USA, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czech Republic, Estonia, Georgia, Hungary, Israel, Italy, South Korea, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Taiwan, Thailand, Ukraine and United Kingdom (NCT01921205) (EudraCT2012-004996-38)
  • 01 Jan 2017 UCB completes a phase III trial in Partial seizures (monotherapy) in USA, Australia, Belgium, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Japan, South Korea, Latvia, Lithuania, Mexico, Philippines, Poland, Portugal, Romania, Russia, Slovakia, Spain, Sweden, Switzerland, Thailand, Ukraine and United Kingdom (PO) (NCT01465997)
  • 20 Dec 2016 Registered for Partial epilepsies (Monotherapy) in European Union, Liechtenstein, Iceland, Norway (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top